Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio announced the grant of stock options for 59,250 shares and RSUs for 12,550 shares to 9 newly hired employees on October 1, 2026, as material inducements to employment. The options have a 10-year term with an exercise price of $18.06 per share and vest over four years. The company continues advancing telitacicept through Phase 3 clinical development for autoimmune diseases, with enrollment completed in the UPSTREAM MG trial and expansion into ocular myasthenia gravis.